U.S. Markets closed

Stemline Therapeutics: 3Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Thursday reported a loss of $14.9 million in its third quarter.

The New York-based company said it had a loss of 34 cents per share.

The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share.

The biopharmaceutical company posted revenue of $13.3 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $13.4 million.

Stemline Therapeutics shares have risen almost 10% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.44, a fall of 30% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML